Overview

Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD)

Status:
Completed
Trial end date:
2005-04-01
Target enrollment:
Participant gender:
Summary
To determine the safety and tolerability of multiple ascending fixed oral doses of SRA-333 in subjects with mild to moderate Alzheimer's disease.
Phase:
Phase 2
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer